The Pain Pill That Paralyzes Your Gut | The Angry Gut, Chapter 21

Opioid-induced constipation · screening

Opioid-Induced Constipation: Screening in Long-Term Therapy

Opioid-induced constipation is common, under-reported and usually charted as a nuisance. Structured questioning finds it, and the attention and metabolic burden that travels with long-term therapy needs measurement of its own.

Opioid-induced constipation is among the most predictable consequences of long-term opioid therapy and among the least systematically screened. It is usually charted in a side-effect field, managed with a softener, and not revisited. The chapter video The Pain Pill That Paralyzes Your Gut, from The Angry Gut (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes), argues that the bowel effect belongs on the problem list. For the treating physician the practical questions are how to find it, how to stratify risk by agent and dose, what the note should reflect, and which associated deficits can be measured in the same patient.

Why does opioid-induced constipation go unreported?

Waiting for patients to volunteer the complaint misses a large share of cases. In 1,200 European cancer pain patients on opioids, 59.5% met Rome IV criteria, and only 61.5% of those self-identified as constipated. Prescribing did not close the gap: 72% had a regular laxative or peripherally acting antagonist prescribed, only 66% took it daily, and newer agents were used relatively rarely. That cohort had no non-opioid comparison group, so part of the burden reflects advanced disease.

A patient survey of 322 people on an opioid plus a laxative found 81% constipated, 45% under three stools a week and 58% straining; a third had missed, decreased or stopped their opioid to defecate. The survey recruited symptomatic patients online, so treat the figures as an upper bound. The operational point survives: a structured bowel question at each renewal visit finds what an open-ended review does not, and it surfaces self-directed dose changes the prescriber otherwise never hears about.

Risk stratification by agent and dose

In a Northwest England cohort of 80,475 non-cancer pain patients, with codeine as reference, severe constipation hazard ratios were morphine 1.59, oxycodone 1.46, fentanyl 1.37 and tramadol 0.80, with combination products highest at 1.85 (95% CI 1.66-2.06). Against under 50 MME daily, the 50 to under 120 band carried 1.95 and the band at 120 and above 1.45 (95% CI 1.32-1.60), an inversion most plausibly explained by prophylaxis and closer monitoring at high dose. The endpoint was an enema or suppository given in hospital, so outpatient burden is undercounted.

The effect reaches the esophagus: 24% of 225 chronic users referred for manometry had opioid-induced esophageal dysfunction, 31% on oxycodone, 28% on hydrocodone and 12% on tramadol. Tolerance develops to analgesia but not to the bowel effect, which persists and requires long-term management. A stable patient on an unchanged dose is therefore not a resolved case.

How is opioid-induced constipation treated?

The peripheral effect is separable from central analgesia. In the COMPOSE trials, naldemedine responders reached 47.6% versus 34.6% and 52.5% versus 33.6% on placebo, against a demanding definition held for 9 of 12 weeks. Overall adverse events matched placebo; gastrointestinal events roughly doubled, 40 versus 18 and 42 versus 20. Neither abstract reports an analgesia endpoint. Across 27 randomized trials and 9,149 patients, naloxone and naldemedine ranked most efficacious, with relative risks of non-response of 0.65 and 0.66.

Class caveats matter. Alvimopan was restricted to inpatient use after an association with myocardial infarction, and naloxegol at 25 mg did not restore codeine-slowed transit in opioid-naive volunteers. Lubiprostone improved bowel movement response, 27.1% versus 18.9%, without quality-of-life benefit and with abdominal pain in 7.1% versus 0%. The 2023 Japanese guidelines place naldemedine as a primary option because conventional laxatives address the stool rather than the receptor. Agent selection is the prescriber’s decision; the screening job is to make sure the problem reaches the list.

What are narcotic bowel syndrome and opioid-induced hyperalgesia?

I was taught that opioids silence the migrating motor complex. Human recordings show intravenous morphine inducing out-of-cycle duodenal phase III-like activity in nine of ten subjects, abolished by atropine: contraction without propagation. Narcotic bowel syndrome, abdominal pain that worsens despite continued or escalating dosing, develops in roughly 6% of long-term users and is considered centrally mediated. Across 27 trials and 1,630 surgical patients, higher intraoperative dosing produced worse postoperative pain, small and below usual clinically important thresholds but consistent in direction. In 67 dose-reduction studies, pain, function and quality of life improved in every fair-quality study measuring them, although only 3 studies were rated good and 51 poor.

The practice position links these through metaflammation: a stagnant first brain feeding systemic inflammation that amplifies central pain. That bridge rests on tissue and animal work. A pilot comparing 18 long-term users with 22 opioid-naive back pain patients found only minor plasma cytokine differences, and plasma is downstream of the mucosa. The social layer compounds it, since patients who avoid eating before going out withdraw, and isolation drives chronic pain.

What to measure beyond the bowel

Transit scintigraphy, antroduodenal manometry and breath testing are gastroenterology studies performed elsewhere, not part of Measura [Cardiometabolic and Autonomic Health Analysis]. Breath tests warrant caution here: in 525 consecutive glucose breath tests, post-surgical patients on more motility-depressing drugs were less likely to test positive (HR 0.752), suggesting the test may track transit speed. What Measura can add in the same patient:

Cognitive assessment. In the same pilot, long-term users performed significantly worse on attention and reported lower pain self-efficacy. A documented baseline makes later change interpretable and supports fall-risk and functional decisions.
Laboratory panels and bioimpedance body composition. The diabetes, fatty liver and depression that remove patients from trials are the terrain long-term opioid patients carry; measuring it gives the metabolic side of a pain plan a number.
Autonomic nervous system testing. The duodenal effect is cholinergic, but cardiovascular and sudomotor autonomic studies do not assess enteric function, and no cited study connects them to constipation. Order them for independent autonomic indications, not as a bowel surrogate.

Documentation and workflow

Move opioid-induced constipation from the side-effect field to the problem list, record stool frequency and straining at each renewal, and document any patient-initiated dose changes. A standing order for screening can attach a cognitive baseline to long-term therapy, and between-visit monitoring carries the bowel question forward. Falls and cognition pair in cognitive assessment and fall prevention, and staffing and workflow covers who asks. The trial-level detail is in The Angry Gut deep dive on the narcotic bowel. The patient version is narcotic bowel syndrome for patients, and PPI and B12 deficiency screening covers acid suppression.

Frequently asked questions

How should opioid-induced constipation be screened in primary care?

Ask directly at every renewal rather than relying on spontaneous report, because about four in ten patients meeting Rome IV criteria do not describe themselves as constipated. Record weekly stool frequency, straining and any self-directed dose changes, and chart the finding on the problem list so it is reviewed rather than carried forward in a side-effect field. Review the selection criteria.

Does tolerance develop to opioid-induced constipation?

No. Tolerance develops to analgesia, which drives dose escalation, while the bowel effect persists and requires long-term management. Each escalation adds bowel burden without a compensating adaptation. A patient on a stable dose who stopped mentioning constipation should be asked again, not assumed resolved. Read the clinical rationale.

Which opioids and doses carry the highest constipation risk?

In a cohort of 80,475 non-cancer pain patients, combination products carried the highest hazard ratio at 1.85, followed by morphine at 1.59 and oxycodone at 1.46, with tramadol below codeine at 0.80. Risk was elevated from 50 MME daily. Because the endpoint required in-hospital intervention, community burden is larger than these rates. See specialty applications.

Why assess cognition in patients on long-term opioids?

In a cross-sectional pilot of chronic low back pain, long-term opioid users performed significantly worse on attention and had lower pain self-efficacy than patients with the same pain not taking opioids. The sample was small, but a documented baseline lets later change be measured and informs fall-risk and functional decisions. Read about cognitive assessment.

Can Measura measure gut motility in opioid-treated patients?

No. Scintigraphy, manometry and breath testing are gastroenterology studies performed elsewhere. Measura reports cognitive, laboratory, body composition and autonomic findings to the ordering physician. Autonomic studies assess cardiovascular and sudomotor regulation, not enteric function, so a normal result does not exclude opioid-induced bowel dysfunction. See guidance on interpreting the report.

What is opioid bowel syndrome?

Opioid bowel syndrome, usually called narcotic bowel syndrome, is abdominal pain that gets worse even while opioid dosing continues or rises. It develops in roughly 6% of long-term users and is considered centrally mediated, meaning the nervous system amplifies the pain rather than the bowel alone producing it. It belongs on the problem list next to the constipation. Read what testing shows in narcotic bowel syndrome.

What is the best laxative for opioid constipation?

Conventional laxatives address the stool, not the opioid receptor in the gut, which is why the 2023 Japanese guidelines place naldemedine as a primary option. Across 27 randomized trials and 9,149 patients, naloxone and naldemedine ranked most efficacious. Tolerance never develops to the bowel effect, so the choice matters for as long as therapy continues. Agent selection belongs to the prescriber; the screening job is getting the problem onto the list.

Screen the whole patient on long-term therapy

Learn how the Measura protocol fits cognitive, laboratory and body composition testing into a practice’s long-term medication review workflow.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Davies, A., Fagan, N., Gonzalez-Barboteo, J., Chelazzi, C., Economos, G., Elsner, F., Leach, C., Monsen, R. E., Oldenmenger, W. H., Remi, C., van den Beuken-van Everdingen, M., & Wüstefeld, M. (2024). Inadequate management of opioid-induced constipation in European cancer pain patients: Results of a real-world, multicentre, observational study (“E-StOIC”). Supportive Care in Cancer, 32(10), 701. https://doi.org/10.1007/s00520-024-08898-1
Bell, T. J., Panchal, S. J., Miaskowski, C., Bolge, S. C., Milanova, T., & Williamson, R. (2009). The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European patient survey (PROBE 1). Pain Medicine, 10(1), 35-42. https://doi.org/10.1111/j.1526-4637.2008.00495.x
Yimer, B. B., Soomro, M., McBeth, J., Medina, C. R. R., Lunt, M., Dixon, W. G., & Jani, M. (2025). Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: A retrospective cohort study in Northwest England. BMC Medicine, 23(1), 288. https://doi.org/10.1186/s12916-025-04118-7
Snyder, D. L., Crowell, M. D., Horsley-Silva, J., Ravi, K., Lacy, B. E., & Vela, M. F. (2019). Opioid-induced esophageal dysfunction: Differential effects of type and dose. The American Journal of Gastroenterology, 114(9), 1464-1469. https://doi.org/10.14309/ajg.0000000000000369
Hale, M., Wild, J., Reddy, J., Yamada, T., & Arjona Ferreira, J. C. (2017). Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): Two multicentre, phase 3, double-blind, randomised, parallel-group trials. The Lancet Gastroenterology & Hepatology, 2(8), 555-564. https://doi.org/10.1016/S2468-1253(17)30105-X
Luthra, P., Burr, N. E., Brenner, D. M., & Ford, A. C. (2019). Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: Systematic review and network meta-analysis. Gut, 68(3), 434-444. https://doi.org/10.1136/gutjnl-2018-316001
Drossman, D., & Szigethy, E. (2014). The narcotic bowel syndrome: A recent update. American Journal of Gastroenterology Supplements, 2(1), 22-30. https://doi.org/10.1038/ajgsup.2014.6
Albrecht, E., Grape, S., Frauenknecht, J., Kilchoer, L., & Kirkham, K. R. (2020). Low- versus high-dose intraoperative opioids: A systematic review with meta-analyses and trial sequential analyses. Acta Anaesthesiologica Scandinavica, 64(1), 6-22. https://doi.org/10.1111/aas.13470
Frank, J. W., Lovejoy, T. I., Becker, W. C., Morasco, B. J., Koenig, C. J., Hoffecker, L., Dischinger, H. R., Dobscha, S. K., & Krebs, E. E. (2017). Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review. Annals of Internal Medicine, 167(3), 181-191. https://doi.org/10.7326/M17-0598
Richards, G. C., Lluka, L. J., Smith, M. T., Haslam, C., Moore, B., O’Callaghan, J., & Strong, J. (2018). Effects of long-term opioid analgesics on cognitive performance and plasma cytokine concentrations in patients with chronic low back pain: A cross-sectional pilot study. Pain Reports, 3(4), e669. https://doi.org/10.1097/PR9.0000000000000669